Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-10-20
2000-05-23
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514318, 514326, 514255, 546189, 546193, 546208, 544360, 544365, A61K 31445, C07D40112
Patent
active
06066651&
ABSTRACT:
Orally-active nipecotamide glycolamide ester derivatives of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.
REFERENCES:
patent: 5273982 (1993-12-01), Alig et al.
patent: 5430024 (1995-07-01), Alig et al.
patent: 5770575 (1998-06-01), Beavers et al.
Hoekstra W J et al., Design and Evauation of Nonpeptide Fibrinogen Gamma-Chain Based GPIIB/IIIA Antagonists; Jan. 1, 1995; pp. 1582-1592.
Hoekstra WJ et al., Solid Phase Parallel Synthesis Applied to Lead Optimization: Discovery of Potent Analogues of the GPIIB/IIIA Antagonists RWJ-50042; Oct. 22, 1996; pp. 2371-2376.
Hoekstar W J et al., Solid Phase Synthesis Via N-Terminal Attachment to the 2-Chlorotrityl Resin; Apr. 14, 1997; pp. 2629-2632.
Esters of N,N-Disubstituted 2-Hydroxyacetamides as a Novel Highly Biolabile Prodrug Type for Carboxylic Acid Agents; Mar. 1987; pp. 451-454.
Appollina Mary A.
McKane Joseph K.
Ortho-McNeil Pharmaceutical , Inc.
LandOfFree
Orally-active nipecotamide glycolamide esters for the treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally-active nipecotamide glycolamide esters for the treatment , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally-active nipecotamide glycolamide esters for the treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837327